Objectives: To examine the association between glycosylated haemoglobin (HbA1c) and fatty liver markers. Methods: This cross-sectional analysis stratified subjects into quintiles based on HbA1c. Fatty liver using ultrasonography scores (FLUS) were assigned as follows: 2 points, moderate or severe fatty liver; 1 point, mild fatty liver; and 0 points, normal liver. Subjects with viral hepatitis, alcohol intake >175 g/week or receiving hypoglycaemic treatment were excluded. Results: The study included 5384 subjects. Serum cholinesterase (ChE) and FLUS showed a significant graded increase with increasing HbA1c. In linear regression analysis stratified by body mass index (BMI) and age, ChE and FLUS were significantly associated with lower (1 þ 2) and higher (3 þ 4 þ 5) HbA1c quintiles, respectively, independent of BMI and age. Conclusions: The findings show that both ChE and FLUS are significantly correlated with HbA1c, independent of BMI and age.
Introduction
The metabolic syndrome is known to cause atherosclerosis, and is defined as central obesity (indicated by waist circumference) plus any two of the following factors: elevated triglycerides, reduced highdensity-lipoprotein cholesterol (HDL-C), elevated blood pressure and elevated fasting plasma glucose. 1 The metabolic syndrome is associated with non-alcoholic fatty liver disease (NAFLD) 2 and is correlated with serum alanine aminotransferase (ALT) concentration in a dose-dependent manner (within the reference range), 3 suggesting that NAFLD and ALT concentration can be used in tandem to identify at-risk subjects. 4 Elevated aminotransferases are also independently associated with the metabolic syndrome in patients with diabetes who have no ultrasonographic evidence of fatty liver. 5 Since insulin resistance is a key mechanism of NAFLD, the metabolic syndrome and glycaemic disorder, 6 NAFLD is also independently associated with HbA1c concentration in non-diabetic individuals. 7 The FIN-D2D survey reported in 2010 that the prevalence of the metabolic syndrome and type 2 diabetes are significantly increased in subjects with NAFLD compared with those with normal liver function tests. 8 It is likely that NAFLD is associated with both the metabolic syndrome and glycaemic disorder (as indicated by HbA1c), but ultrasonographic findings and ALT concentrations may not be definitive markers of fatty liver in all individuals. Serum cholinesterase (ChE) concentration is increased in patients with fatty liver, but few studies have investigated the direct association between glycaemic disorder and ChE and other markers of fatty liver. A single, small-scale study found that ChE concentrations were higher in patients with non-alcoholic steatohepatitis (NASH), which was also associated with diabetes. 9 The aim of this preliminary study, therefore, was to examine the hypothesis that fatty liver (diagnosed via ultrasonography) and ChE are associated with HbA1c.
Subject and methods

Study population
This cross-sectional retrospective analysis included workers or retirees aged between 19 and 90 years who were undergoing an annual medical check-up as part of the healthcare system at Jikei University Hospital Health Care Centre, Tokyo, Japan between January 2006 and December 2006. Exclusion criteria were: (i) treatment with hypoglycaemic agents; (ii) hepatitis B surface antigen positive; (iii) hepatitis C antibody positive; and (iv) ethanol intake >175 g/week.
All participants provided written informed consent prior to enrolment in the study. The study was approved by the Institutional Review Board of Jikei University School of Medicine and carried out in accordance with the Declaration of Helsinki.
Ultrasonography
Experienced technicians, who were unaware of the aims of the study and blinded to laboratory findings, evaluated fatty liver via abdominal ultrasonography. All medical sonographers were registered with the Japan Society of Ultrasonics in Medicine and had been trained at Jikei University Hospital. Study-specific fatty liver using ultrasonography scores (FLUS) were assigned as follows: 2 points, moderate or severe fatty liver (deep attenuation, vascular blurring, a fatty bandless sign and/or a brighter liver compared with the spleen [10] [11] [12] ); 1 point, mild fatty liver (bright liver, focal fatty sparing 10 and/or high hepato-renal echo contrast 11, 13 ); and 0 points, normal liver.
Data collection
Medical history and lifestyle information including alcohol consumption and smoking were documented by a professional nurse. Subject height and weight were recorded with subjects dressed in lightweight indoor clothes, and body mass index (BMI) calculated as weight/height 2 (kg/m 2 ). Waist circumference while undressed and standing was measured (to the nearest cm) using a nonelastic soft tape at the umbilical level when the navel was between the lowest rib and the level of the iliac crest, or midway between the lowest rib and the level of the iliac crest. Blood pressure (BP) was measured using a standard mercury manometer after 5 min rest in a sitting position. Following the blood pressure measurement, venous blood specimens (12 ml for serum and 1.8 ml for plasma) were drawn between 09:00 and 10:30 hours, after an overnight fast. Plasma and serum were stored at 10-15 C prior to analysis within 4 h.
Laboratory analyses
Fasting plasma glucose (FPG) concentrations were determined using the glucose oxidase immobilized oxygen electrode method (GA08III; A&T Corporation, Kanagawa, Japan).
14 HbA1c (NGSP equivalent value) 15 was determined with high-performance liquid chromatography (HLC-723G9; Tosoh Corporation, Tokyo, Japan). Enzymatic methods were used to analyse serum high-density-lipoprotein cholesterol (HDL-C) (MetaboLead HDL-C; Kyowa Medex, Tokyo, Japan), lowdensity-lipoprotein cholesterol (LDL-C) and triglyceride (TG) (Cholestest LDL and Cholestest TG, respectively; Sekisui Medical, Tokyo, Japan), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (AST-J2 and ALT-J2, respectively; Wako Pure Chemical Industries, Osaka, Japan). Serum ChE and g-glutamyltransferase (GGT) levels were determined using a butyrylthiocholine iodide method and g-glutamyl-3-carboxy-4-nitroanilide method (both Wako Pure Chemical Industries, Ltd, Osaka, Japan), respectively. Serum hepatitis B virus surface antigen and hepatitis C virus antibody (3rd generation) were quantified by chemiluminescent enzyme immunoassay (CLEIA) (Architect i2000SR; Abbott Japan, Tokyo, Japan). Serum C-reactive protein (CRP) and uric acid were quantified by latex agglutination immunoassay (Iatro CRP-EX, Mitsubishi Chemical Medicine Corporation, Tokyo, Japan) and uricase peroxidase method (Wako Pure Chemical Industries), respectively. All samples were analysed in the same laboratory at Jikei University Hospital.
Statistical analyses
Subjects were stratified into sex-specific quintile groups by HbA1c concentration (groups 1/5 to 5/5). The same HbA1c cutoff points are applied to both men and women in clinical practice, but subjects were stratified by sex in the present study in order to permit analyses of possible sex-specific differences. Participant characteristics were presented as mean AE SD for continuous variables and proportions (%) for dichotomous variables. The association between HbA1c and all other variables was evaluated as a trend-test with linear regression models for continuous variables and logistic regression models for dichotomous variables.
In addition, the numbers of individuals evaluated for ChE and FLUS were tested with the Jonckheere-Terpstra test. Multiple regression models stratified by BMI and age were further used to evaluate determinants of HbA1c. Subjects were stratified according to median BMI and age for the linear regression analysis. The analysis was also performed with stratifications for HbA1c quintiles in order to test for differences in associations between those with lower and those with higher quintiles.
Stata statistical package version 10.1 (StataCorp LP, College Station, Texas, USA) was used for statistical analysis. P-values < 0.05 were considered statistically significant.
Results
The study recruited 7984 subjects (5437 male/2547 female; mean age, 48.8 years; age range, 19-90 years). A total of 2600 subjects were excluded (receiving hypoglycaemic agents n ¼ 248; alcohol consumption >175 g/week n ¼ 2216; hepatitis B positive n ¼ 51; hepatitis C positive n ¼ 29; missing HbA1c data n ¼ 56). The final analysis included 5384 subjects (3173 male/2211 female; mean age, 48.0 years; age range, 19-90 years). A total of 5167 subjects underwent ultrasonography and were assigned FLUS scores. Serum ChE levels were determined in 3973 subjects. Demographic and clinical characteristics of the subjects stratified by sex and HbA1c quintile are given in Tables 1a and 1b. In both men and women, there was a significant graded increase in BMI, mean age and FPG from quintile 1 to quintile 5 (P < 0.001 for each trend; Tables 1a and 1b) .
Data regarding the metabolic syndrome and hepatic function markers are shown in Tables 1a and 1b . Waist circumference, TG, and systolic and diastolic BP showed a significant graded increase, and HDL-C was significantly decreased from quintile 1 to quintile 5 in both men and women (P < 0.001 for each trend). In addition, there were significant graded increases in AST and ALT from quintile 1 to quintile 5 in both men and women (P < 0.001 for each trend).
Linear regression analysis of subjects stratified according to median BMI (22.3 kg/m 2 ) indicated that FLUS score was significantly associated with HbA1c independent of BMI in the total study population (P < 0.001 for each association; Tables 2a and 2b ). The association in quintiles 3 þ 4 þ 5 combined ( ¼ 0.138, P < 0.001 and ¼ 0.144, P < 0.001 for BMI 22.3 kg/m 2 and >22.3 kg/m 2 , respectively; Tables 2a and 2b) contributed to these findings. In addition, ChE was also significantly associated with HbA1c independent of BMI in the total study population (P < 0.001 for each association; Tables 2a  and 2b ). In subgroup analysis, the association in quintiles 1 þ 2 combined ( ¼ 0.126, P < 0.001; Table 2a ) contributed to the findings in the total study population, as well as in subjects with BMI >22.3 kg/m 2 (Table 2b) .
Results of linear regression analysis of subjects stratified according to median age (46 years) are given in Tables 3a and 3b . HbA1c was significantly associated with FLUS in all subjects (P < 0.001 for each association; Tables 3a and 3b ). The association in quintiles 3 þ 4 þ 5 combined ( ¼ 0.258, P < 0.001 and ¼ 0.114, P ¼ 0.001 for age 46 and >46 years, respectively; Tables 3a and 3b) contributed to these findings. HbA1c was also significantly associated with ChE in all subjects (P < 0.05 ;  Tables 3a and 3b ). The association in quintiles 1 þ 2 combined ( ¼ 0.107, P ¼ 0.003 and ¼ 0.149, P ¼ 0.001 for age 46 and >46 years, respectively; Tables 3a and 3b) contributed to these findings.
Sequential changes in the value of suggested that ChE was correlated more strongly with HbA1c than FLUS in lower ChE, cholinesterase; FLUS, fatty liver using ultrasonography scores. ChE, cholinesterase; FLUS, fatty liver using ultrasonography scores. FLUS, fatty liver using ultrasonography scores; NS, not statistically significant (P ! 0.05); ChE, cholinesterase; BP, blood pressure; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDL-C, low-densitylipoprotein cholesterol; GGT, g-glutamyltransferase; CRP, C-reactive protein; TG, triglyceride. Table 3a . Standardized linear regression analysis of determinants of glycosylated haemoglobin (HbA1c) in subjects aged 46 years, in the total study population and when stratified according to HbA1c quintile.
Parameter
All subjects n ¼ 2700 HbA1c quintiles (1 þ 2), while FLUS was more important than ChE in higher quintiles (3 þ 4 þ 5).
Discussion
Since the establishment of the concept of NAFLD and non-alcoholic steatohepatitis (NASH), the role of fatty liver in metabolic disease has become of interest. Fatty liver markers within or slightly above the upper limit of the normal range have been shown to be pathogenic, and fatty metamorphosis of hepatocytes leads to insulin resistance, [16] [17] [18] with optimum levels of metabolic markers being below mean values in healthy subjects in modern developed countries. 7, [19] [20] [21] [22] Fatty liver markers are not included among the criteria of the metabolic syndrome, however. We therefore compared the criteria of the metabolic syndrome with fatty liver markers in terms of glycaemic status.
There is a lack of consensus regarding the ideal marker for glycaemic status, particularly in the postprandial state. Although elevated FPG increases medical care costs in patients with impaired fasting glucose, 23 post-challenge hyperglycaemia is associated with death and macrovascular complications even before the development of overt diabetes. 24 Slightly elevated HbA1c is useful as it suggests a history of slightly raised plasma glucose, especially in the postprandial state, 25 and this has been found to be significantly associated with increased mortality even in people without diabetes. [26] [27] [28] Although HbA1c is an internationally recognised marker of glycaemic status, 29 it is not included among the criteria for the metabolic syndrome.
Plasma ChE is a pseudocholinesterase found primarily in the liver, and it is increased in patients with fatty liver, nephrotic syndrome, Grave's disease and hepatocellular carcinoma. [30] [31] [32] [33] In the present study, only two individuals had nephrotic syndrome and their exclusion did not influence the results. Patients with overt and untreated Grave's disease and hepatocellular carcinoma were not included in the annual health check-up, and were therefore not enrolled in the study cohort. ChE is known to decrease in patients with hypothyroidism, liver cirrhosis, fulminant hepatitis or sepsis, and those undergoing kidney dialysis or who are pregnant. 32, 34 Patients with these conditions were also not included in the annual health check-up programme. Elevated ChE was associated with HbA1c in subjects in quintiles 1 þ 2 in the present study. This may lead to worsening of HbA1c status, as indicated by the association between HbA1c and FLUS points in quintiles 3 þ 4 þ 5.
It has been suggested that biochemical fatty liver markers be included among the criteria of the metabolic syndrome, 35 but previous fatty liver indices did not include ChE. 7, 36 Elevated ChE was significantly associated with raised HbA1c in the present study.
Data from the present study indicate an increase in ALT from quintile 1 to quintile 5. ALT is used in the scoring system during selection of patients for liver biopsy, 37 and for scoring NASH and the risk of incident diabetes. 36, 38 Elevated ALT can be used to predict the onset of type 2 diabetes and the metabolic syndrome even within the upper limit of the normal range, 19, 20 and increased ALT within the normal range is associated with cardiovascular risk factors independent of obesity. 21 A Korean study found a direct association between aminotransferase concentration (even within the normal range) and mortality from liver disease. 22 Nevertheless, ChE and FLUS were shown to be better markers of fatty liver than ALT in our present study.
Overt NAFLD has been identified as a risk factor for type 2 diabetes in Japanese subjects. 39 Magnetic resonance imaging is the most reliable noninvasive imaging method for assessing intrahepatic content, 40, 41 but ultrasonography is the most commonly available resource and gives a high degree of certainty during diagnosis of fatty liver in large cohort studies. 13, 42 Quantitative techniques aimed at evaluation of fatty liver by ultrasonography have yet to be established. Ultrasonography has been used to assess the presence or absence of fatty liver and to determine the proportion of subjects with NAFLD. 7 There is a positive correlation between the degree of fatty changes and an increase in echogenicity, 11 however, and we therefore attempted to evaluate fatty liver quantitatively via FLUS. A bright liver, focal fatty sparing or high hepato-renal echo contrast indicates mild fatty liver, as described. 10, 11, 13 Since fatty changes <10-20% cannot be reliably detected by ultrasonography, 11 ChE may be a useful marker in these subjects. Fatty liver diagnosed with ultrasonography (FLUS) was significantly associated with raised HbA1c in higher quintiles in the present study. A slight elevation in ChE level was associated with glycaemic status as indicated by lower HbA1c in the current study (quintiles 1 þ 2), whereas FLUS scores were important in higher quintiles (3 þ 4 þ 5 combined). This result is in line with the findings of others, 5 and may explain why there is no study reporting that fatty liver detected by ultrasonography is generally associated with the full spectrum of HbA1c.
The present study is limited by the fact that the data were not sufficient to provide cause-effect analysis due to its cross-sectional nature. It is not possible to determine whether higher HbA1c leads to more severe fatty liver/ChE or whether higher fatty liver scores/ChE result in higher HbA1c. Longitudinal studies are required to clarify this issue. The present study did not include specific details of antihypertensive drug treatment. In addition, patients with undiagnosed or untreated diabetes may have been included in our analysis as we did not perform oral glucose tolerance testing. Although smoking is a known risk factor for diabetes, 43 smoking (self-reported information) was not significantly associated with HbA1c in the present study. In addition, FLUS and ChE data were not available for all participants. It is not possible, therefore, to exclude the possibility that these issues might impact on our findings.
In conclusion, our study shows that a slight elevation in plasma ChE is correlated with lower HbA1c quintile, while FLUS is important thereafter (independent of BMI and age). A change in marker from ChE to FLUS was observed with increasing HbA1c. Both ChE and FLUS are significantly correlated with HbA1c level and are therefore useful markers, although their contribution may be at different ends of the HbA1c distribution. These markers may enable early intervention, which is known to have a beneficial effect on the improvement of fatty liver. 44 
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